Toolkit · Cannabis

The Cannabis Law Toolkit

21 U.S.C. §§ 801

Type
Toolkit
Jurisdiction
National
Date
2026-12-08
Topic
Cannabis

Cannabis law is not one body of law but a permanent collision between two of them: marijuana remains a Schedule I controlled substance under the federal Controlled Substances Act, and it is simultaneously a licensed, taxed, heavily regulated commercial product in most states. This toolkit maps that collision pillar by pillar — federal prohibition and enforcement discretion, state licensing regimes, municipal control, banking under the Bank Secrecy Act, the punitive tax rule of IRC § 280E, intellectual property without a federal trademark, employment policy, real estate and leasing, insurance, the illegality defense in contract, the unavailability of bankruptcy, and the hemp and CBD sideshow. It closes with the professional-responsibility question every lawyer in this space must answer before taking the engagement. Each pillar gives you the doctrine, the anchor authority, and the UpLaw guides and checklists that go deeper. Federal law is in motion: a rescheduling proceeding has been pending, and banking legislation has repeatedly stalled — verify the current federal status before you rely on anything here. This toolkit describes the law and its risks; it is not a roadmap for violating federal law.

The Cannabis Law Toolkit

Cannabis > Cannabis Law | Published 8 December 2026 - Updated 5 January 2027 | UpLaw - uplaw.us

Every hard question in cannabis law is the same question wearing a different hat: what happens when a state licenses, taxes, and inspects a business that federal law still calls a criminal enterprise? Answer that once, and the tax rule, the banking rule, the trademark rule, and the bankruptcy rule all fall out of it.

Keywords: cannabis law, Controlled Substances Act, Schedule I, Section 280E, cannabis banking, Bank Secrecy Act, FinCEN guidance, cannabis licensing, local control, cannabis trademark, cannabis employment, cannabis real estate, illegality defense, bankruptcy unavailability, hemp and CBD

How to read this toolkit

This is a resource map, not a treatise and not a compliance manual. It walks thirteen pillars of cannabis practice. Under each one you get the doctrine in plain English, the anchor authority that actually governs, the trap that catches people, and links into the UpLaw guides, articles, and checklists that go deeper.

Three ground rules before you start.

First, the one fact. Marijuana is a Schedule I controlled substance under the federal Controlled Substances Act, 21 U.S.C. §§ 801–971. Manufacturing, distributing, or possessing it with intent to distribute violates 21 U.S.C. § 841 regardless of what any state has legalized. State legalization does not repeal federal law; it removes the state's criminal prohibition and substitutes a licensing regime. Every other pillar in this toolkit is a downstream consequence of that fact.

Second, the law is moving. Federal rescheduling has been under active administrative consideration, and cannabis banking legislation has passed one chamber of Congress repeatedly without being enacted. Anything you read about federal status — here or anywhere — must be re-verified as of the day you advise. This toolkit describes the law and the risks it creates. It does not tell anyone how to evade federal law, and no lawyer should.

Third, state law is the operative law and it is not uniform. There is no national cannabis code. Licensing, product rules, potency caps, residency requirements, advertising limits, employment protections, and local-control rules differ state by state and often city by city. Treat every state-law statement here as a framework, and confirm your jurisdiction's actual rule.

Start with the companion guide, Cannabis Law: A Comprehensive Guide to State Legalization and Federal Prohibition, for the full doctrinal treatment. When you are ready to actually stand a licensed operation up, work Cannabis Business Licensing and Compliance: A Practical Checklist.

Our running example. Thornfield Grove, Inc. is a fictional multi-state operator: cultivation and a retail dispensary in State A (adult-use), a medical-only dispensary in State B, and a newly acquired hemp-derived beverage line sold nationally. We will drag Thornfield Grove through every pillar and watch what breaks.

The cannabis landscape at a glance

  • Pillar 1 — Federal prohibition. The CSA, Gonzales v. Raich, enforcement discretion, and why "the feds don't really enforce it" is a risk posture, not a legal defense.
  • Pillar 2 — State licensing. Application, ownership disclosure, seed-to-sale tracking, and the residency and social-equity fights.
  • Pillar 3 — Local control. The municipal veto, buffer zones, and conditional use permits.
  • Pillar 4 — Banking. The Bank Secrecy Act, FinCEN guidance, SAR filing, and the cash problem.
  • Pillar 5 — Tax. IRC § 280E, cost of goods sold, and the effective rate that kills businesses.
  • Pillar 6 — Intellectual property. No federal trademark for plant-touching goods; what to do instead.
  • Pillar 7 — Employment. Drug testing, off-duty use statutes, and the split on accommodation.
  • Pillar 8 — Real estate. Forfeiture, § 856, lender consent, and the cannabis-specific lease.
  • Pillar 9 — Insurance. Coverage gaps, contraband exclusions, and public-policy voiding.
  • Pillar 10 — Contracts. The illegality defense and how courts have actually ruled.
  • Pillar 11 — Insolvency. No bankruptcy. Receivership and assignments for benefit of creditors instead.
  • Pillar 12 — Hemp and CBD. The 2018 Farm Bill, the FDA's position, and intoxicating hemp derivatives.
  • Pillar 13 — Professional responsibility. Model Rule 1.2(d) and whether you can ethically take the engagement.

Pillar 1 — Federal prohibition: the CSA, Raich, and enforcement discretion

Marijuana sits on Schedule I of the CSA, 21 U.S.C. § 812(c), which is reserved for substances with a high potential for abuse, no currently accepted medical use, and no accepted safe use under medical supervision. From that classification everything else follows: § 841 (manufacture and distribution), § 846 (conspiracy), 18 U.S.C. § 2 (aiding and abetting), 21 U.S.C. § 856 (maintaining drug-involved premises), 21 U.S.C. § 881 (civil forfeiture), and 18 U.S.C. §§ 1956–1957 (money laundering, because the proceeds are proceeds of "specified unlawful activity").

Congress's power to reach even purely intrastate, non-commercial cannabis was settled in Gonzales v. Raich, 545 U.S. 1 (2005), which upheld application of the CSA to homegrown marijuana cultivated for personal medical use under California law. The Court reasoned that Congress may regulate purely local activity that is part of a class of activities substantially affecting interstate commerce. Four years earlier, United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001), had rejected a medical-necessity defense to the CSA. There is no "but my state said yes" defense in federal court.

What has changed is not the law but the enforcement posture. The 2013 Cole Memorandum set out federal enforcement priorities and effectively deprioritized prosecution of state-compliant operators; it was rescinded in January 2018. Do not cite it as protection. The one genuine legal constraint is the appropriations rider (commonly called Rohrabacher–Farr, later Rohrabacher–Blumenauer), which bars the Department of Justice from spending funds to prevent states from implementing their medical marijuana laws. The Ninth Circuit held in United States v. McIntosh (9th Cir. 2016) that the rider bars DOJ from prosecuting individuals in strict compliance with state medical marijuana law while the rider is in effect. Three limits matter enormously: the rider must be renewed each fiscal year, it covers medical only (not adult-use), and it protects only conduct in strict compliance with state law.

A rescheduling proceeding — moving marijuana from Schedule I to Schedule III — has been pending in the administrative process. Understand precisely what it would and would not do. Schedule III would end the application of IRC § 280E (which by its terms reaches only Schedule I and II trafficking). It would not make state-licensed sales federally lawful, would not cure the banking problem on its own, and would leave marijuana an unapproved new drug under the Federal Food, Drug, and Cosmetic Act. Verify the current federal status before advising.

For the criminal-exposure architecture that sits behind all of this — corporate charging, conspiracy, aiding and abetting, responsible-corporate-officer theories — see White-Collar Crime and Corporate Criminal Liability: A Comprehensive Guide.

Thornfield Grove: its board minutes should reflect that directors understand the operation is federally illegal, that they have been advised of the risk, and that they have chosen to proceed. That is a fiduciary-process point, not a defense. See Corporate Governance and Fiduciary Duties: A Comprehensive Guide for Directors and Officers.

Pillar 2 — State legalization regimes and licensing

A large majority of states permit medical cannabis, and roughly half have authorized adult use. Those counts change; verify. What is stable is the architecture of a state regime:

  • A licensing authority (a cannabis control commission, a department of revenue, or an agriculture agency) with rulemaking power.
  • License categories — cultivation, manufacturing/processing, distribution, testing laboratory, retail/dispensary, delivery, sometimes on-site consumption. Some states mandate vertical integration; others forbid it; most sit in between.
  • Ownership and control disclosure — fingerprinting, background checks, source-of-funds reporting, and disclosure of every direct and indirect owner above a threshold. Undisclosed "true parties of interest" are the single most common cause of license denial and revocation.
  • Seed-to-sale tracking — mandatory inventory tracking software, with reconciliation obligations and hard limits on transfers.
  • Testing, labeling, packaging, and potency rules, plus child-resistant packaging and health warnings.
  • Advertising restrictions — audience-composition thresholds, prohibitions on appeals to minors, and mandatory disclaimers.
  • Residency and social equity provisions — and here is a live constitutional fight. Courts have split on whether the dormant Commerce Clause applies to a market that is federally illegal. The First Circuit held that Maine's residency requirement for medical dispensary ownership violated the dormant Commerce Clause (Northeast Patients Group v. United Cannabis Patients and Caregivers of Maine, 1st Cir. 2022); other courts have reasoned that there is no lawful interstate market for the Clause to protect. Expect continued litigation.

Because cannabis is federally illegal, there is also no lawful interstate commerce. Product cultivated in State A cannot be shipped to State B, even between two legal states. That is why multi-state operators like Thornfield Grove are not really one business; they are a stack of separate, state-siloed businesses tied together by management-services agreements, IP licenses, and brand standards — a structure that looks and functions a great deal like franchising. If you have not thought about it that way, read The Franchise Law Toolkit and ask whether your MSO's brand-licensing arrangement is inadvertently a franchise under state franchise and business-opportunity statutes.

Deep dives: the licensing mechanics live in Cannabis Business Licensing and Compliance: A Practical Checklist. Entity formation, governance, and the ordinary business-law scaffolding live in The Small Business Legal Toolkit and Incorporating a Startup the Right Way: A Founder's Legal Checklist. Advertising limits interact with general false-advertising law — see Advertising Law: A Comprehensive Guide to the FTC Act and Lanham Act, The Advertising and Marketing Law Toolkit, and Substantiating Advertising Claims: A Practical Checklist, and note that health claims about cannabis or CBD products invite FDA and FTC attention independent of state cannabis rules.

Pillar 3 — Local control, zoning, and the municipal veto

A state license is a permission slip, not a right to operate. Most legalizing states expressly preserve local control — California's framework, for example, allows local jurisdictions to ban commercial cannabis activity outright — and a large share of municipalities have opted out. The practical sequence is: local approval first, state license second. Applicants who sign a lease before securing local entitlements routinely lose both.

The local layer typically involves:

  • Opt-in/opt-out ordinances and license caps or lotteries at the municipal level.
  • Zoning districts in which cannabis uses are permitted, conditionally permitted, or prohibited.
  • Buffer/sensitive-use setbacks — minimum distances from schools, parks, daycares, churches, and often other dispensaries. Measure them the way the ordinance says to measure them (property line to property line vs. door to door changes outcomes).
  • Conditional use permits or special use permits, often discretionary and often appealable by neighbors.
  • Odor, security, lighting, and hours-of-operation conditions, plus community benefit or host-community agreements.

Everything you know about land use applies here, only with a hostile political overlay. Work Land Use and Zoning Law: A Comprehensive Guide and The Land Use and Development Toolkit; when the site needs relief, run Obtaining a Zoning Variance or Special Use Permit: A Practical Checklist and, for a ground-up build, Securing Land Use Entitlements for a Development Project: A Practical Checklist.

Thornfield Grove: its State B dispensary sits 940 feet from a parochial school. The ordinance requires 1,000 feet measured from the nearest property line. Thornfield measured door-to-door and got 1,120. That single measurement convention is the whole case.

Pillar 4 — Banking and financial services

The banking problem is not that banks dislike cannabis. It is that cannabis proceeds are proceeds of federal drug trafficking, and a bank that knowingly accepts them risks exposure under the money-laundering statutes, 18 U.S.C. §§ 1956 and 1957, and under the Bank Secrecy Act, 31 U.S.C. § 5311 et seq., which imposes anti-money-laundering program, know-your-customer, and suspicious-activity-reporting obligations.

The only meaningful accommodation is administrative guidance: FinCEN's FIN-2014-G001, "BSA Expectations Regarding Marijuana-Related Businesses" (Feb. 14, 2014). It does not legalize anything. It tells financial institutions that if they choose to bank a marijuana-related business, they must conduct enhanced due diligence and file suspicious activity reports in one of three categories:

  • "Marijuana Limited" — the institution believes the customer is compliant with state law and does not implicate enforcement priorities.
  • "Marijuana Priority" — the institution believes the customer implicates an enforcement priority or violates state law.
  • "Marijuana Termination" — the institution is terminating the relationship.

Because FIN-2014-G001 was drafted against the (now-rescinded) Cole Memorandum priorities, its foundation is unstable — another reason banking access remains thin, expensive, and concentrated in credit unions and a modest number of state-chartered banks with dedicated compliance teams. Card networks generally will not process plant-touching transactions, which pushes operators toward cash, ACH workarounds, and "cashless ATM" schemes that have drawn regulatory and network enforcement. Federal legislation to create a safe harbor for cannabis banking has repeatedly advanced and repeatedly failed to become law; do not assume it has passed — confirm.

The consequences ripple: a cash-intensive business faces heightened theft risk, currency-transaction-reporting obligations, structuring exposure under 31 U.S.C. § 5324 (never, ever break deposits up to stay under a threshold — that is itself a federal crime), and brutal diligence in any M&A process. Buyers should assume source-of-funds review will be the longest chapter of the deal. See Conducting Merger and Acquisition Due Diligence: A Practical Checklist.

Pillar 5 — Taxation and Section 280E

This is the pillar that decides whether a cannabis business is viable.

IRC § 280E denies any deduction or credit for amounts paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances within the meaning of Schedule I or II of the CSA. It was enacted after a drug dealer successfully deducted business expenses. It applies to state-licensed cannabis operators with full force, and it has been repeatedly upheld.

What survives § 280E is cost of goods sold. COGS is not a deduction; it is subtracted in arriving at gross income, and Congress cannot tax gross receipts as if they were income. So the tax planning in this industry is, bluntly, an inventory-accounting exercise under IRC §§ 471 and 263A: what can properly be capitalized into inventory (cultivation labor, growing supplies, direct production costs) and what cannot (selling, general and administrative expense — the entire retail floor, marketing, most executive compensation).

The case law you need:

  • Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner (CHAMP), 128 T.C. 173 (2007) — a taxpayer with a genuinely separate, non-trafficking trade or business (there, caregiving services) may allocate expenses to that business and deduct them. This is the origin of the "two-business" structure.
  • Olive v. Commissioner (9th Cir. 2015) — but the second business must be real. A vaporizer lounge that gave away yoga and movies alongside cannabis sales was one business, not two.
  • The Tax Court's Harborside decision, affirmed on appeal, tightened the screws further: it rejected an expansive COGS theory for a retailer and confirmed that a reseller's inventoriable costs are narrow.

The practical result is an effective federal tax rate that can exceed 70% of book profit for retail-heavy operators, and negative cash flow at apparently healthy margins. Retailers fare worse than cultivators, because cultivators can capitalize far more into inventory.

Thornfield Grove, worked through the arithmetic. Its State A dispensary posts $10,000,000 in revenue, $6,000,000 in cost of goods sold, and $3,000,000 in operating expenses (payroll for the retail floor, rent, security, marketing, management fees). Book profit is $1,000,000. For federal tax purposes, § 280E disallows the entire $3,000,000 of operating expense: taxable income is revenue minus COGS, or $4,000,000. At a 21% corporate rate the federal liability is $840,000 on $1,000,000 of book profit — an effective rate near 84%, before any state tax. Now change one fact. Move the same $10,000,000 of revenue to the cultivation entity, where a far larger share of labor and overhead is properly capitalized into inventory under §§ 471 and 263A, and COGS might legitimately be $8,500,000 — taxable income of $1,500,000, tax of $315,000. Same economics, radically different tax, driven entirely by what the Code lets you push below the gross-income line. That is the whole game, and it is why the structuring of a cannabis operator is a tax question first and a corporate question second. It is also why the numbers must be built with tax counsel and an accountant who know this area — the line between properly capitalized inventory costs and disallowed SG&A is exactly where the IRS audits, and Harborside shows how narrow a reseller's side of that line really is.

Note the rescheduling connection: § 280E reaches only Schedule I and Schedule II. If marijuana is moved to Schedule III, § 280E stops applying prospectively. That is the single largest economic stake in the rescheduling proceeding. It is also why refund-claim and protective-amended-return strategies have been widely discussed — and why they should be evaluated with tax counsel, not assumed.

Deep dives: Business Taxation: A Comprehensive Guide to Entity Choice and Federal Income Tax, The Business Tax Toolkit, Choosing a Tax Entity: A Practical Checklist, and — because cannabis operators are audited at elevated rates — Handling an IRS Audit and Tax Controversy: A Comprehensive Guide.

Entity choice interacts badly with § 280E: pass-through structures push non-deductible expense to the owners' returns, and C corporations trap it at the entity. There is no clean answer, only a modeled one.

Pillar 6 — Intellectual property without federal trademark registration

Federal trademark registration requires lawful use in commerce under the Lanham Act, 15 U.S.C. § 1051 et seq. The USPTO applies that requirement as a bar: use that violates federal law is not "use in commerce" that can support registration. See TMEP § 907. The TTAB refused registration on this ground in In re Morgan Brown (TTAB 2016) (retail store services featuring marijuana) and In re JJ206, LLC (TTAB 2016) (cannabis vaporizers). The rule is simple and unforgiving: you cannot federally register a mark for plant-touching goods or services.

So what can Thornfield Grove do?

  1. State trademark registration. Available in legalizing states, cheap, and real — but geographically limited to the state.
  2. Common-law rights. Trademark rights arise from use, not registration. They are territorially bounded by the market penetration of the use. See Three Tiers of Trademark Protection: Common-Law Rights, Supplemental, and Principal Registers and Unregistered Trademark Rights at Common Law: Priority, Geography, and the Tea Rose-Rectanus Doctrine.
  3. Ancillary federal registrations. Register the brand for goods and services that are federally lawful — clothing, education, entertainment, media, hemp-derived topicals that comply with federal law. This builds a federal registration portfolio around the brand even though the core goods are unregistrable. Do it carefully and honestly: a specimen or description of goods that misdescribes what you actually sell invites fraud-on-the-Office allegations. Start with From Brand Idea to Registered Mark: A Trademark Registration Toolkit and Registering a Trademark With the USPTO: A Complete Guide.
  4. Copyright. Copyright has no lawful-use requirement. Package art, label design, photography, advertising copy, and website content are protectable under 17 U.S.C. § 102 exactly as they would be for any other business. This is a genuinely underused asset in the industry.
  5. Trade secrets. Genetics, cultivar selection, extraction parameters, nutrient regimes, and customer data are classic trade secrets. Whether a federal Defend Trade Secrets Act claim (18 U.S.C. § 1836) is available to a federally illegal business is an open and litigated question; state UTSA claims are the safer route. Either way, protection depends on reasonable measures to maintain secrecy — which means NDAs, access controls, and an exit process. See Trade Secret Protection Toolkit: Building and Defending a Confidentiality Program and Trade Secret Law: How Secrecy Becomes Protectable Intellectual Property.
  6. Licensing. The MSO brand-license is the workhorse of this industry — and it must be drafted against state rules that may treat a licensor as a "true party of interest" requiring disclosure or licensure. See Drafting a Trademark License Agreement: A Practical Checklist, and remember that a trademark license without quality control is a naked license that can forfeit the mark.

Pillar 7 — Employment and workplace policy

Two questions dominate: can you test, and must you accommodate?

Federal law offers the employee nothing. The ADA excludes from protection an individual currently engaging in the illegal use of drugs, 42 U.S.C. § 12114(a), and marijuana is illegal under federal law — the Ninth Circuit so held in James v. City of Costa Mesa (9th Cir. 2012). Federal contractors and grantees face the Drug-Free Workplace Act, 41 U.S.C. § 8101 et seq. Safety-sensitive DOT-regulated positions are governed by 49 C.F.R. Part 40, which has no medical-marijuana exception. For those roles, the analysis is short.

State law is where the fight is, and it is genuinely split.

  • Coats v. Dish Network, LLC, 350 P.3d 849 (Colo. 2015) — Colorado's lawful-off-duty-activities statute did not protect a quadriplegic employee's state-licensed medical marijuana use, because "lawful" means lawful under both state and federal law. The employer won.
  • Barbuto v. Advantage Sales & Marketing, LLC (Mass. 2017) — the opposite direction. Massachusetts recognized a handicap-discrimination claim where an employer fired an employee for off-site medical marijuana use without engaging in the interactive process; accommodation may be reasonable.
  • Noffsinger v. SSC Niantic Operating Co. (D. Conn.) — Connecticut's medical marijuana anti-discrimination provision is enforceable and not preempted by the CSA, the ADA, or the FDCA.
  • A growing set of states now protect off-duty adult use or bar reliance on tests that detect non-psychoactive metabolites. California's AB 2188 (codified at Cal. Gov't Code § 12954) is the leading example; New York, Nevada, Washington, and others have their own versions, with carve-outs for safety-sensitive and federally regulated roles.

Because THC metabolites persist for weeks, a positive urine test proves past use, not present impairment — which is exactly why the newer statutes push employers toward impairment-based standards and away from metabolite testing. Rewrite the drug policy accordingly, state by state, and make sure the handbook does not promise a nationwide rule you cannot lawfully apply in California.

Note also that cannabis employees are employees: the Tenth Circuit held in Kenney v. Helix TCS, Inc. (10th Cir. 2019) that the FLSA covers workers in a state-legal cannabis business notwithstanding the CSA. Wage-and-hour law, discrimination law, and worker classification all apply in full.

Deep dives: The Employment Law Toolkit: From Hiring to Separation, Employment Discrimination Law: A Comprehensive Guide, Building a Legally Sound Employee Handbook, and Drafting an Employee Handbook That Holds Up: A Practical Checklist.

Pillar 8 — Real estate and leasing

The landlord's problem is stated in two statutes. 21 U.S.C. § 856 makes it a federal crime to knowingly lease, rent, or make available for use a place for the purpose of manufacturing, distributing, or using a controlled substance. 21 U.S.C. § 881 authorizes civil forfeiture of real property used to commit or facilitate a CSA violation. Private civil RICO suits by neighboring landowners have also been permitted — the Tenth Circuit allowed such a claim to proceed in Safe Streets Alliance v. Hickenlooper (10th Cir. 2017) — creating a nuisance-plus-RICO theory that has been used to pressure cannabis properties.

Practically, this reshapes the transaction:

  • Financing. Federally regulated lenders will generally not lend against cannabis-occupied property, and standard mortgage covenants prohibit illegal use. Cannabis real estate is financed by private lenders, cannabis REITs, and sale-leasebacks — at a premium.
  • Title insurance and 1031 exchanges can be complicated or unavailable.
  • Lease drafting must be cannabis-specific: an express representation of the intended use, a permitted-use clause that survives a change in state law, regulatory-compliance covenants, license-contingency and license-loss provisions, casualty and destruction-of-crop allocation, above-market security deposits, personal guaranties, forfeiture-risk allocation and indemnity, landlord audit and inspection rights, and a cooperation covenant requiring the tenant to give the landlord whatever the state regulator demands. Standard commercial forms will contain an "illegal use" default clause that, unmodified, makes the tenant in default on day one — find it and fix it.

Run the transaction through The Real Estate Transactions Toolkit, draft against Commercial Leases: A Comprehensive Guide to Negotiating and Drafting, and review with Reviewing a Commercial Lease: A Practical Checklist.

Pillar 9 — Insurance

Cannabis operators are insurable, but thinly, expensively, and mostly through the surplus lines market. The recurring coverage fights:

  • Contraband and illegal-acts exclusions. Standard property forms exclude property in the custody of law enforcement or held illegally; "growing crops" exclusions in commercial property forms can swallow the most valuable asset on the premises.
  • Public policy. Insurers have argued that a court should not enforce a policy covering federally illegal property. A district court in Colorado rejected that argument in Green Earth Wellness Center, LLC v. Atain Specialty Insurance Co. (D. Colo. 2016), enforcing coverage notwithstanding federal illegality — though it enforced other policy exclusions against the insured. An earlier Hawaii federal decision, Tracy v. USAA Casualty Insurance Co. (D. Haw. 2012), went the other way on a homeowner's claim for medical marijuana plants. The doctrine is unsettled; the drafting is what matters.
  • Product liability. Vape-related injuries, contamination, mislabeled potency, and pesticide residue are the live exposures. Confirm the products form does not exclude cannabis.
  • Directors and officers. Available but priced for the risk, and regularly carved back for regulatory investigations.
  • Crime coverage matters more than usual in a cash business, and carriers will impose real security conditions.

Read the policy the way a coverage lawyer reads it: Insurance Coverage Law: A Comprehensive Guide for Policyholders and The Business Insurance and Coverage Toolkit.

Pillar 10 — Contracts and the illegality defense

Ordinary contract law says a promise is unenforceable if enforcement is against public policy. See Restatement (Second) of Contracts §§ 178–179. Every cannabis contract therefore carries a built-in escape hatch: the defaulting party can argue the contract is void because its subject matter is a federal crime. This is not theoretical. It is the first defense filed in cannabis commercial litigation, and it is regularly raised by the party that took the money.

The courts have not lined up neatly, but the trend has favored enforcement:

  • Some federal district courts have declined to void cannabis-related agreements outright, reasoning that enforcing a promise to pay for a business interest does not itself require anyone to violate the CSA — the reasoning in Mann v. Gullickson (N.D. Cal. 2016) is the most-cited example.
  • Others have severed offending provisions (for instance, a promissory note secured by cannabis inventory) while enforcing the remainder.
  • Some have refused relief where the court would have to order performance of a federal crime — a court will not, for example, order specific performance requiring delivery of marijuana.

Drafting responses that actually help:

  • A robust severability clause that survives a finding that one covenant is unenforceable.
  • Arbitration, which keeps the illegality defense in front of an arbitrator who is not a federal court, and whose award is typically confirmable.
  • Choice of law and forum favoring a state court in a legalizing state.
  • Express acknowledgment of federal illegality, plus a mutual waiver of the illegality defense. A waiver will not bind a court's public-policy analysis, but it is powerful evidence that both parties knew and bargained around the risk.
  • Security interests that avoid taking a lien directly on cannabis inventory (which cannot be foreclosed on without a license), and instead reach equity, receivables, licenses (where permitted), and real property.

See The Commercial Contracts Toolkit: Drafting, Reviewing, and Enforcing Business Agreements and, for what a court can actually award if you win, Contract Damages: How Courts Make the Injured Party Whole.

Pillar 11 — Bankruptcy unavailability and the alternatives

A cannabis business cannot get bankruptcy relief. The bankruptcy system is federal: federal judges, a federal trustee, and a federal estate. A trustee cannot administer, sell, or take possession of assets whose possession is a federal crime, and a plan cannot be confirmed if it is "proposed by any means forbidden by law," 11 U.S.C. § 1129(a)(3). The United States Trustee Program has taken the position that cannabis cases should be dismissed, and bankruptcy courts routinely dismiss for cause under 11 U.S.C. § 1112(b) or § 707(a).

The doctrine has grown teeth beyond plant-touching businesses. In In re Arenas (10th Cir. BAP 2015), debtors who leased space to a marijuana grower were denied relief. In In re Way to Grow, Inc. (Bankr. D. Colo. 2018, aff'd D. Colo. 2019), a hydroponics supply company — which never touched the plant — was dismissed because its business depended on customers' CSA violations. There is some countercurrent: the Ninth Circuit in Garvin v. Cook Investments NW (9th Cir. 2019) affirmed confirmation of a plan for a debtor with a cannabis-leasing tenant, reading § 1129(a)(3) to police the proposal of the plan rather than its substance. Do not read that as an open door. Assume bankruptcy is unavailable and plan accordingly.

The alternatives, all of them state-law creatures:

  • State-court receivership. The workhorse. Many cannabis states have adopted procedures allowing a court-appointed receiver to hold or operate a licensed business — sometimes requiring the receiver to be licensed or approved by the regulator. Confirm your state's receivership statute and its cannabis regulator's receiver rules; both must be satisfied.
  • Assignment for the benefit of creditors (ABC). A general assignment to an assignee who liquidates for creditors. Faster and cheaper than receivership, but the license generally cannot be assigned without regulatory approval.
  • Article 9 foreclosure on non-cannabis collateral, plus a negotiated transfer of the entity that holds the license (a change-of-control application, not an asset sale).
  • Out-of-court workouts and composition agreements, which is where most of this actually resolves.
  • Dissolution and winding up under state entity law.

The core insolvency concepts still control your thinking — priority, avoidance, fraudulent transfer, and the absolute priority rule are all instructive even when the federal forum is closed. See Bankruptcy Law: A Comprehensive Guide to Chapters 7, 11, and 13 and The Bankruptcy and Restructuring Toolkit — and read them knowing that the federal remedies they describe are the very ones your client cannot use.

Thornfield Grove: its State A cultivation entity is insolvent. Chapter 11 is off the table. The plan is a state-court receivership with a regulator-approved receiver, a license-preserving change-of-control sale, and an ABC for the non-licensed management entity. Lender consent must be negotiated, not compelled.

Pillar 12 — Hemp, CBD, and intoxicating hemp products

The Agriculture Improvement Act of 2018 (the 2018 Farm Bill) removed hemp from the CSA's definition of marijuana. "Hemp" is defined at 7 U.S.C. § 1639o as Cannabis sativa L. and its derivatives with a delta-9 THC concentration of not more than 0.3% on a dry weight basis. Above that line it is marijuana; at or below it, it is an agricultural commodity, regulated by USDA under approved state or tribal plans.

A sovereignty note before the consequences. The Farm Bill's reference to "state or tribal plans" is not a drafting flourish, and it is the point at which cannabis practice collides with federal Indian law. Tribes are separate sovereigns. A federally recognized tribe is not a subdivision of the state that surrounds it, and tribal law is not a subset of state law. A tribe may submit its own hemp production plan to USDA, and tribes have enacted their own cannabis codes and licensing regimes on their own lands, governed by tribal law and the federal-tribal relationship rather than by the surrounding state's cannabis statute. Whether and how state law reaches conduct in Indian country is a genuinely difficult federal-Indian-law question that turns on the land's status, the parties' membership, and the specific federal statutes at issue — it is not answered by reading the state cannabis code. If your matter touches Indian country, do not assume the state regime applies, do not assume it does not, and bring in counsel who practices federal Indian law. Note also that the CSA is a federal statute of general applicability: tribal legalization no more repeals federal prohibition than state legalization does.

Three consequences, and one enormous loophole.

  1. Hemp is federally lawful, so the downstream disabilities lift. Hemp businesses can bank (with diligence), are not subject to § 280E, and can obtain federal trademark registrations for compliant goods — see USPTO Examination Guide 1-19 (May 2019). That is why the hemp side of Thornfield Grove's business is worth more per dollar of revenue than the marijuana side.
  2. The FDA has not gone away. The agency's position is that CBD cannot lawfully be added to food or marketed as a dietary supplement, because CBD is an active ingredient in an FDA-approved drug (Epidiolex) and is therefore excluded by the FDCA's "prior drug investigation" clause, 21 U.S.C. § 321(ff)(3)(B). FDA has said it will not use existing frameworks and has asked Congress for a new pathway. Enforcement has focused on health claims — a CBD product marketed as treating anxiety, pain, or cancer is an unapproved new drug and a misbranded product. This is the single most common compliance failure in the hemp sector, and it overlaps directly with FTC advertising-substantiation law.
  3. Intoxicating hemp derivatives — delta-8 THC, delta-10, THC-O, HHC, and high-milligram hemp beverages — exploit the fact that the Farm Bill's line is drawn at delta-9 concentration by dry weight. The Ninth Circuit read the statute's plain text to cover hemp-derived delta-8 products in AK Futures LLC v. Boyd Street Distro, LLC (9th Cir. 2022), holding they fell within the Farm Bill definition and could support trademark rights. But: DEA has taken a narrower view of synthetically derived cannabinoids; dozens of states have banned or tightly restricted intoxicating hemp products; and Congress has repeatedly considered closing the loophole in Farm Bill reauthorization. This is the fastest-moving area in the whole field. Verify the current federal and state status before advising on any intoxicating hemp product.

Pillar 13 — Professional responsibility for lawyers advising cannabis clients

You cannot skip this pillar. ABA Model Rule 1.2(d) provides that a lawyer shall not counsel a client to engage, or assist a client, in conduct the lawyer knows is criminal or fraudulent — but may discuss the legal consequences of proposed conduct and may counsel or assist a client to make a good-faith effort to determine the validity, scope, meaning, or application of the law. Read literally against the CSA, helping a client obtain a cannabis license and negotiate a dispensary lease is assisting criminal conduct.

The profession resolved this pragmatically, and it resolved it state by state. Remember the fundamental point: the ABA Model Rules are a model. They bind no one until a jurisdiction adopts them, and adopting jurisdictions vary — California's rules differ notably. Many cannabis states have amended their Rule 1.2 or added a comment expressly permitting a lawyer to advise and assist a client on conduct permitted by that state's cannabis law, provided the lawyer also advises the client on federal law and policy. Colorado, Washington, Illinois, and California are among those that have done so, by rule, comment, or formal ethics opinion. Others have addressed it only by bar opinion, and a handful have not addressed it at all.

Your obligations, wherever you sit:

  • Read your own state's Rule 1.2 and its comments, plus your bar's ethics opinions. Do not rely on the Model Rules, and do not rely on the rule in the state next door.
  • Advise on federal law in writing. Nearly every permissive rule conditions itself on this. Document that the client was told the business is federally illegal, that federal enforcement discretion is not a legal protection, and that bankruptcy, federal trademark, and banking are compromised.
  • Competence (Rule 1.1) — cannabis regulatory law is a specialty; a general business lawyer who does not know § 280E or the true-party-of-interest rules is not competent to advise here.
  • Rule 8.4(b) — criminal conduct reflecting adversely on fitness. Lawyers have been disciplined for personal involvement in cannabis ventures in some jurisdictions even where advising clients is permitted. Investing in your client's grow is not the same as representing it.
  • Fees. Taking an equity fee in a cannabis client implicates Rule 1.8(a) (business transactions with a client) and puts you in the same forfeiture and illegality boat as the client.
  • Trust accounting. Cash retainers from a cannabis client raise BSA and IOLTA questions your bank may not tolerate.

Deep dives: Legal Ethics and Professional Responsibility: A Comprehensive Guide to the Model Rules and The Legal Ethics and Law Practice Management Toolkit.

The landscape as a working checklist

Gate each item before the next stage.

Gate 1 — Threshold

  • [ ] Client advised in writing that marijuana is a Schedule I controlled substance and the venture violates federal law.
  • [ ] Current federal status verified (scheduling proceeding; appropriations rider status; banking legislation).
  • [ ] Your jurisdiction's Rule 1.2 and ethics opinions on advising cannabis clients confirmed.
  • [ ] Engagement letter scopes the representation to state regulatory and business law; no advice on evading federal law.

Gate 2 — Market and license

  • [ ] State regime identified: license types, caps, application windows, scoring criteria.
  • [ ] Every true party of interest disclosed; background checks and source-of-funds ready.
  • [ ] Residency/social-equity requirements assessed (and the dormant Commerce Clause question flagged).
  • [ ] Seed-to-sale tracking, testing, labeling, packaging, and advertising rules mapped.

Gate 3 — Site

  • [ ] Municipality permits the use; opt-out ordinance confirmed absent.
  • [ ] Zoning district correct; buffer distances measured the way the ordinance measures them.
  • [ ] CUP/SUP path and appeal exposure understood; lease contingent on entitlements and license.

Gate 4 — Money

  • [ ] Banking relationship identified and enhanced-diligence package prepared (FinCEN FIN-2014-G001).
  • [ ] No structuring. Cash-handling, CTR, and security protocols documented.
  • [ ] § 280E modeled: COGS/inventory accounting under §§ 471 and 263A; effective rate stress-tested.
  • [ ] Entity structure modeled against § 280E, not just for state tax.

Gate 5 — Assets and people

  • [ ] Federal registrations pursued only for lawful ancillary goods/services; state and common-law rights secured.
  • [ ] Copyright and trade-secret programs stood up.
  • [ ] Drug/impairment policy rewritten state by state; safety-sensitive and DOT roles carved out.
  • [ ] Wage-hour, classification, and discrimination compliance in place — cannabis employees are employees.

Gate 6 — Risk and exit

  • [ ] Insurance placed; contraband, growing-crops, and products exclusions reviewed line by line.
  • [ ] Every contract has severability, arbitration, choice of law, and an acknowledged-illegality clause.
  • [ ] Security interests avoid direct liens on cannabis inventory.
  • [ ] Insolvency plan assumes bankruptcy is unavailable: receivership and ABC paths pre-identified, regulator's receiver rules confirmed.

Primary Authority

Federal statutes

Regulations and agency guidance

  • FinCEN, FIN-2014-G001, BSA Expectations Regarding Marijuana-Related Businesses (Feb. 14, 2014)
  • 49 C.F.R. Part 40 (DOT drug and alcohol testing)
  • TMEP § 907 (lawful use in commerce); USPTO Examination Guide 1-19 (May 2019) (cannabis and cannabis-related marks after the 2018 Farm Bill)
  • Cole Memorandum (Aug. 29, 2013) — rescinded January 2018; cite for history only, never as protection

Cases

  • Gonzales v. Raich, 545 U.S. 1 (2005) (Commerce Clause reaches intrastate cultivation)
  • United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001) (no medical-necessity defense)
  • Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007) (separate non-trafficking business may deduct)
  • Olive v. Commissioner (9th Cir. 2015) (§ 280E applies; second business must be genuine); Patients Mutual Assistance Collective Corp. ("Harborside") (Tax Ct., aff'd 9th Cir.) (narrow COGS for resellers)
  • United States v. McIntosh (9th Cir. 2016) (appropriations rider bars DOJ prosecution of strict state-medical compliance)
  • Coats v. Dish Network, LLC, 350 P.3d 849 (Colo. 2015) (no off-duty protection; "lawful" means lawful federally too)
  • Barbuto v. Advantage Sales & Marketing, LLC (Mass. 2017) (handicap-discrimination claim available); Noffsinger v. SSC Niantic Operating Co. (D. Conn.) (state anti-discrimination provision not preempted)
  • James v. City of Costa Mesa (9th Cir. 2012) (ADA does not protect medical marijuana use)
  • Kenney v. Helix TCS, Inc. (10th Cir. 2019) (FLSA covers cannabis workers)
  • Safe Streets Alliance v. Hickenlooper (10th Cir. 2017) (private civil RICO claim by neighboring landowners may proceed)
  • In re Arenas (10th Cir. BAP 2015); In re Way to Grow, Inc. (Bankr. D. Colo. 2018, aff'd D. Colo. 2019) (dismissal; cannabis-dependent businesses); Garvin v. Cook Investments NW (9th Cir. 2019) (plan confirmation affirmed under § 1129(a)(3))
  • Green Earth Wellness Center, LLC v. Atain Specialty Insurance Co. (D. Colo. 2016) (policy not void on public-policy grounds); Tracy v. USAA Casualty Insurance Co. (D. Haw. 2012) (contra, homeowner's claim)
  • In re Morgan Brown (TTAB 2016); In re JJ206, LLC (TTAB 2016) (no federal registration absent lawful use)
  • AK Futures LLC v. Boyd Street Distro, LLC (9th Cir. 2022) (hemp-derived delta-8 within Farm Bill definition)
  • Northeast Patients Group v. United Cannabis Patients and Caregivers of Maine (1st Cir. 2022) (residency requirement violated dormant Commerce Clause)

Secondary sources and model rules

  • ABA Model Rules of Professional Conduct 1.1, 1.2(d), 1.4, 1.8(a), 8.4(b) — a model only; the binding rules are your adopting jurisdiction's, and they vary
  • Restatement (Second) of Contracts §§ 178–179 (unenforceability on grounds of public policy)
  • McCarthy on Trademarks and Unfair Competition (lawful-use requirement); Collier on Bankruptcy (dismissal for cause)

Related UpLaw Resources

Related Guides & Articles

Related Checklists

Related Toolkits

This toolkit is general legal information from UpLaw (uplaw.us), not legal advice, and does not create an attorney-client relationship. Marijuana remains a Schedule I controlled substance under federal law; nothing here counsels or assists anyone in violating federal law. Cannabis law is state-specific and changing rapidly at both the state and federal level — verify current requirements, including the current federal scheduling status, and consult qualified counsel in your jurisdiction before acting.